Log in

Sartorius Stedim Biotech Stock Price, Forecast & Analysis (EPA:DIM)

€135.20
-0.20 (-0.15 %)
(As of 11/14/2019 08:36 AM ET)
Today's Range
€134.70
Now: €135.20
€136.40
50-Day Range
€121.70
MA: €129.53
€136.70
52-Week Range N/A
Volume9,864 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Sartorius Stedim Biotech SA produces and sells instruments and consumables for the biopharmaceutical industry worldwide. It offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as systems for storage and transportation of intermediate and finished biological products. Read More…

Industry, Sector and Symbol

Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone33 4 42 84 56 00

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive DIM News and Ratings via Email

Sign-up to receive the latest news and ratings for DIM and its competitors with MarketBeat's FREE daily newsletter.


Sartorius Stedim Biotech (EPA:DIM) Frequently Asked Questions

What is Sartorius Stedim Biotech's stock symbol?

Sartorius Stedim Biotech trades on the EPA under the ticker symbol "DIM."

Has Sartorius Stedim Biotech been receiving favorable news coverage?

News articles about DIM stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sartorius Stedim Biotech earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Sartorius Stedim Biotech.

Who are some of Sartorius Stedim Biotech's key competitors?

What other stocks do shareholders of Sartorius Stedim Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sartorius Stedim Biotech investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP), Ardelyx (ARDX), ArQule (ARQL) and Athersys (ATHX).

Who are Sartorius Stedim Biotech's key executives?

Sartorius Stedim Biotech's management team includes the folowing people:
  • Dr. Joachim Kreuzburg, Chairman & CEO (Age 54)
  • Mr. Heiko Imöhl, VP of Group Financing & Investor Relations
  • Ms. Petra Kirchhoff, VP of Corp. Communications & IR (Age 50)
  • Mr. Gerry Mackay, Exec. VP of Marketing, Sales & Services for Lab Products and Services Division (Age 56)

What is Sartorius Stedim Biotech's stock price today?

One share of DIM stock can currently be purchased for approximately €135.20.

What is Sartorius Stedim Biotech's official website?

The official website for Sartorius Stedim Biotech is http://www.sartorius.com/.

How can I contact Sartorius Stedim Biotech?

The company can be reached via phone at 33 4 42 84 56 00.


MarketBeat Community Rating for Sartorius Stedim Biotech (EPA DIM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  59
MarketBeat's community ratings are surveys of what our community members think about Sartorius Stedim Biotech and other stocks. Vote "Outperform" if you believe DIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel